Navigation Links
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
Date:5/6/2013

ray BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.   Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma under in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib (an Array-invented drug) in non-small cell lung cancer and thyroid cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the timing of completion or initiation of further trials involving MEK162, selumetinib, ARRY-520, ARRY-614 and danoprevir, the potential for the results of ongoing clinical trials to support regulatory approval or the marketing success of these drugs, and future plans to progress and develop these drugs. These statements involve significant risks and uncertainties, including those discussed in the most recent annual report filed on Form 10-K, quarterly reports filed on Form 10-Q, and other reports filed by Array with the Securi
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:
... Calif., Oct. 10 Amgen (Nasdaq:  AMGN) today ... pivotal Phase 3 trials comparing denosumab to Zometa® ... the prevention of skeletal related events (SREs) in ... separate analyses, denosumab demonstrated a clinically meaningful, consistent ...
... Oct. 8 The American Dental Association (ADA) has ... ), the largest provider of health care products and ... at $860,000 to students in the Community Dental Health ... initially for hands-on clinical training in the program, which ...
Cached Medicine Technology:Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 2Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 3Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 4Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 5Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 6Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 7Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 8Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 9Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 10Henry Schein Inc. Donates Equipment to ADA Community Dental Health Coordinator Pilot Program 2Henry Schein Inc. Donates Equipment to ADA Community Dental Health Coordinator Pilot Program 3
(Date:7/13/2014)... TX (PRWEB) July 13, 2014 The Pearland, ... children ranging in age from four months to 12 years ... and karate classes to birthday parties and Summer Camps, is ... Little Gym of Pearland after spending over six ... of roles, including Gym Director. , Berry has over ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... 13, 2014 According to the Kidney Disease ... step by step guide on what to do to eliminate ... quickly. Vkool writes in its review that readers can easily ... to revitalize their kidney health. Vkool also informs in its ... reverse their damaged kidney functions naturally. The book consists of ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they will ... Senior Living Community in Palatine, IL. The group, called “New ... Wednesdays of every month. This group will begin on ... 55 S. Greeley St. Palatine, IL 60067. It is ... for the group. , “A grief support group is ...
(Date:7/12/2014)... 13, 2014 According to the new ... Systems, Airborne Systems, and Naval Systems) - Global Forecasts ... Security and Surveillance Radar market are estimated to be ... a CAGR of 5.97% to reach $8.61 billion by ... with 47 figures spread through 161 pages and in-depth ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4
... a startling find. Around 75 percent of whites or those ... of developing heart diseases. And that’s not all. These genes ... diabetes. ,The findings, made by two independent groups of ... even if they do not have clear risk factors such as ...
... American doctor has threatened to mobilise US congressmen and senators ... Information (RTI) Act in a case relating to his crusade ... Saha, whose wife died of alleged wrongful treatment in India ... my senators and congressmen in US and will ask them ...
... Human Resource Development in collaboration with National AIDS Control ... Adolescence Education Programme (AEP) which is being implemented by ... ,The Programme is aimed at the ... of the major concerns, i.e. process of growing up ...
... that can enable the blind to hear what they cannot see ... texts through an embedded system and converts them into voice that ... can only read text, but later it is likely to pick ... that took six months to develop the device and the software ...
... to detect epidemic diseases has entered the phase of clinical ... methods that rely on antigen or antibody test, the new ... DNA or RNA, to confirm epidemic diseases such as hepatitis ... Centre of US National Institutes of Health (NIH). ...
... and women who consumed higher levels of calcium and vitamin ... brain lesions, regions of damage// that can increase risk of ... Payne and her co-investigators from Duke and the University of ... men and women (79 men, 153 women) between the ages ...
Cached Medicine News:Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Higher Intake of Calcium and Vitamin D Linked With Brain Lesions in Older People 2
... The Asnis III™ Cannulated Screw System has ... and TCS Systems and combined them to ... screws in both titanium and stainless steel. ... System is designed to optimize surgical outcomes ...
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
... a wide variety of cannulated screw products. ... partially threaded and fully threaded versions. , ... and 7.0 mm products. These incorporate innovative ... a little easier. Ratchet screwdrivers have proven ...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
Medicine Products: